Skin Cancer/Melanoma

CURE spoke with Betsy Hamlin, who was treated with Keytruda Qlex in a clinical trial after being diagnosed with melanoma.

CURE spoke with melanoma survivor Betsy Hamlin about her experience with subcutaneous Keytruda in a clinical trial.

This guide provides a supportive overview of stage 2 melanoma, covering diagnosis, treatment options, and key questions for your medical team.

Dr. Vishal Patel explains what Libtayo’s FDA approval means for patients with high-risk cutaneous squamous cell carcinoma.

The FDA has approved Libtayo for the postsurgical treatment of adults with cutaneous squamous cell carcinoma.

Non-melanoma skin cancer is a common and highly treatable type of cancer that originates in the top layer of the skin, like basal cell carcinoma.

For me, standing up to cancer means honoring my wife’s melanoma journey by raising awareness, supporting early detection and research.

Stage 1 melanoma is treatable with surgery, and when combined with early detection, proper care and regular follow-ups, it offers a favorable outlook.

DecisionDx-SCC may help doctors more accurately guide treatment in high-risk cutaneous squamous cell carcinoma, the second most common form of skin cancer.

Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in unresectable/advanced melanoma.

Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects.

Patients with skin cancer who were fed a high-fiber diet showed better response rates to treatment and longer event-free survival, according to data from the DIET trial.

Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for patients with high-risk skin cancer.

Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

TIL therapy is on the rise in melanoma, with potential for other tumor types.

A significant development in the treatment of advanced melanoma has recently emerged: tumor-infiltrating lymphocyte (TIL) therapy.

Melanoma care varies by stage, with early cases being treated with surgery, whereas advanced disease often requires immunotherapy or targeted therapy.

The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity.

I would like to nominate Ashley Tullio, RN, for the Extraordinary Healer Award for Oncology Nursing.

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.

I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and trust in God’s plan.

The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when enucleation has been recommended.